表紙
市場調査レポート

オーダーメイド医療に関する提携契約:取引動向、企業、財務および予測

Global Personalized Medicine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 230295
出版日 ページ情報 英文 891 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
オーダーメイド医療に関する提携契約:取引動向、企業、財務および予測 Global Personalized Medicine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日: 2016年04月01日 ページ情報: 英文 891 Pages
概要

当レポートでは、オーダーメイド医療に関する提携契約動向について分析し、オーダーメイド医療に関するビジネス活動の概要、主な契約内容を検証し、実際の契約文書を参照した結果をお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 オーダーメイド医療関連取引動向

  • イントロダクション
  • 過去数年のオーダーメイド医療提携
  • オーダーメイド医療に最も積極的な大手製薬会社
  • オーダーメイド医療に関する提携:契約タイプ別
  • オーダーメイド医療に関する提携:治療分野別
  • オーダーメイド医療に関する提携に対する開示された金融条件
    • 取引総額
    • 前金支払額
    • 目標達成報奨金
    • ロイヤルティ料率

第3章 主なオーダーメイド医療取引

  • イントロダクション
  • 金額トップ契約

第4章 オーダーメイド医療に最も積極的な取引企業

  • イントロダクション
  • オーダーメイド医療に最も積極的な取引企業
  • オーダーメイド医療に最も積極的な提携企業プロファイル

第5章 オーダーメイド医療契約取引一覧

  • イントロダクション
  • オーダーメイド医療契約取引一覧

第6章 オーダーメイド医療契約:技術タイプ別

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連資料

付録

  • 付録1:オーダーメイド医療契約(企業別A-Z)
  • 付録2:オーダーメイド医療契約(開発ステージ別)
    • 創薬
    • 前臨床
    • フェーズ?
    • フェーズ?
    • フェーズ?
    • 規制
    • 上市
    • 処方
  • 付録3:オーダーメイド医療契約(タイプ別)
    • 資産購入
    • 譲渡
    • 大手製薬会社のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同上市
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売
    • 株式購入
    • 評価
    • 譲与
    • ジョイントベンチャー
    • ライセンシング
    • 訴訟
    • 製造
    • マーケティング
    • 物質移動
    • オプション
    • プロモーション
    • 研究
    • 合意
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 契約解除
    • 保証
  • 付録4:オーダーメイド医療契約(治療分野別)
  • 付録5:契約タイプの定義

Wildwood Venturesについて

Current Partnering Current Agreements CurrentPartneringの発行タイトル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2108

The Global Personalized Medicine Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.

The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Personalized Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine technologies and products.

Key benefits

Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Personalized Medicine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
  • Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
  • Identify most active Personalized Medicine dealmakers since 2010
  • Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Personalized Medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

  • Trends in Personalized Medicine dealmaking in the biopharma industry since 2010
  • Analysis of Personalized Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Personalized Medicine deals
  • Access to Personalized Medicine contract documents
  • Leading Personalized Medicine deals by value since 2010
  • Most active Personalized Medicine dealmakers since 2010

In Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,370 Personalized Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Personalized Medicine Partnering 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of Personalized Medicine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
  • Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
  • Identify most active Personalized Medicine dealmakers since 2010
  • Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine dealmaking

  • 2.1. Introduction
  • 2.2. Personalized Medicine partnering over the years
  • 2.3. Most active Personalized Medicine dealmakers
  • 2.4. Personalized Medicine partnering by deal type
  • 2.5. Personalized Medicine partnering by therapy area
  • 2.6. Deal terms for Personalized Medicine partnering
    • 2.6.1 Personalized Medicine partnering headline values
    • 2.6.2 Personalized Medicine deal upfront payments7
    • 2.6.3 Personalized Medicine deal milestone payments
    • 2.6.4 Personalized Medicine royalty rates

Chapter 3 - Leading Personalized Medicine deals

  • 3.1. Introduction
  • 3.2. Top Personalized Medicine deals by value

Chapter 4 - Most active Personalized Medicine dealmakers

  • 4.1. Introduction
  • 4.2. Most active Personalized Medicine dealmakers
  • 4.3. Most active Personalized Medicine partnering company profiles

Chapter 5 - Personalized Medicine contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Personalized Medicine contracts dealmaking directory

Chapter 6 - Personalized Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Personalized Medicine deals by company A-Z

Appendix 2 - Personalized Medicine deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Personalized Medicine deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Personalized Medicine deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Personalized Medicine partnering since 2010
  • Figure 2: Active Personalized Medicine dealmaking activity- 2010 to 2016
  • Figure 3: Personalized Medicine partnering by deal type since 2010
  • Figure 4: Personalized Medicine partnering by disease type since 2010
  • Figure 5: Personalized Medicine deals with a headline value
  • Figure 6: Personalized Medicine deals with an upfront value
  • Figure 7: Personalized Medicine deals with a milestone value
  • Figure 8: Personalized Medicine deals with a royalty rate value
  • Figure 9: Top Personalized Medicine deals by value since 2010
  • Figure 10: Most active Personalized Medicine dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top